As a country, Saudi Arabia wants to match the well-established regulatory systems of North America, Europe, and Japan, but adding a halal component, which is of…
In Conversation
mAbxience has a different business model than the majority of big biosimilars producers which have vast sales and marketing capabilities. We have a business-to-business (B2B) model,…
Today, international companies can see the value and the benefit of collaborating with Saudi businesses due to societal changes and government support
We are opening a new chapter in medicine. The early 2000s were focused on monoclonal antibodies, 2015 to 2025 is all about immune therapy, but 2025…
I really care about having operational people on the ground because, in the generics business, if you are not fast, you lose
Vision 2030 is a big opportunity, a north star that challenges each one of us to bring our best and contribute to Saudi Arabia's future
We have an important focus on the Saudi market and further expansion is planned from our side, strengthening our presence, expanding and growing the team while…
Genmab has strong, focused investment into its pipeline and capabilities and is now transitioning into a fully-integrated commercial company. We have made lots of progress, but…
We will continue to diversify our partnerships and expand the geographical scope of our suppliers around the world
We hope that our new Saudi HTA agency, with the help of all other stakeholders such as our DPEC, will soon be fully functioning and generating…
It takes an average of seven years for a patient to see an audiologist from the onset of their hearing loss. However, the impact on the…
We have observed big improvements in terms of trust [in biosimilars] from both healthcare professionals and patients [in Spain] in the last few years
